ライフサイエンスコーパス: valvular disease

1 lications such as pulmonary hypertension and valvular disease.

2 art valves and uncommonly observed in native valvular disease.

3 prone to developing severe aortic disease or valvular disease.

4 g former drinkers and those with significant valvular disease.

5 c dysfunction is the result of aortic and/or valvular disease.

6 mic heart disease, heart failure, and severe valvular disease.

7 on as a potential genetic basis for calcific valvular disease.

8 explain the association of aortic vessel and valvular disease.

9 nd NOTCH mutations are associated with adult valvular disease.

10 the engineering of effective treatments for valvular disease.

11 accepted as the gold standard for therapy of valvular disease.

12 ng therapeutic alternative for patients with valvular disease.

13 ss has been made in the evaluation of mitral valvular disease.

14 n patients with both congenital and acquired valvular disease.

15 ay include carotid artery disease or cardiac valvular disease.

16 e insights into the molecular basis of adult valvular disease.

17 aking antiarrhythmic drugs, or patients with valvular disease.

18 sis, livedo racemosa, or APS-related cardiac valvular disease.

19 ad significant aortic regurgitation or other valvular disease.

20 No patient had coronary artery or primary valvular disease.

21 ring follow-up, in most cases as a result of valvular disease.

22 didates for percutaneous treatment of common valvular diseases.

23 ormal sinus rhythm, and other structural and valvular diseases.

24 nt genetic component in death resulting from valvular diseases.

25 cular disease (11.7%, 10.8%, and 17.6%), and valvular disease (16.7%, 21.2%, and 35.8%), increased, a

26 e heart failure (1.73, 1.22-2.46; p=0.0024), valvular disease (2.47, 1.70-3.58; p<0.0001), stroke as

27 scular disorders (39%), alcohol abuse (36%), valvular disease (32%), liver disease (30%), diabetes (2

28 The main pathogeneses were valvular disease (36%) and hypertension (28%).

29 s, (18)F-NaF PET/CT has been shown to assess valvular disease activity and progression, providing mec

30 s include catheters, AV grafts, and calcific valvular disease, all in conjunction with frequent acces

31 tions of high-energy phosphate metabolism in valvular disease and cardiomyopathy to the clinical seve

32 valve structures is the most common form of valvular disease and is characterized by the appearance

33 ibrillation is associated with more advanced valvular disease and noncardiac comorbidities.

34 cularization is a recognized feature of many valvular diseases and is established by numerous angioge

35 e of coronary artery disease, heart failure, valvular disease, and arrhythmia by 45 years of age was

36 h as coronary artery disease, heart failure, valvular disease, and arrhythmia.

37 comorbidities (including aortic dissection, valvular disease, and arrhythmias) following diagnosis o

38 e, cardiomyopathies, ischemic heart disease, valvular disease, and cardio-oncology; (3) to explore th

39 ing atherosclerosis, pulmonary hypertension, valvular disease, and fibroelastosis.

40 RIC) study who were in sinus rhythm, free of valvular disease, and had acceptable quality 3-dimension

41 ic disease, hypertension, heart failure, and valvular disease, and it is a strong predictor of increa

42 on, diabetes, ventricular failure, rheumatic valvular disease, and prior stroke or other embolic even

43 myocardial infarction, atrial fibrillation, valvular disease, and revascularization procedures).

44 quently have stenotic, regurgitant, or mixed valvular disease, and this valvular dysfunction is incre

45 lder, had a higher incidence of diabetes and valvular disease, and were more likely to be presenting

46 uch as hypertension, ischemic heart disease, valvular diseases, and endocrine disorders.

47 fraction <40%, moderate-to-severe left-sided valvular disease (aortic/mitral stenosis or regurgitatio

48 l included the following: moderate or severe valvular disease (aortic/mitral stenosis or regurgitatio

49 s of left ventricular growth in two types of valvular diseases - aortic stenosis and mitral regurgita

50 Moderate or severe valvular diseases are notably common in this population

51 ypertrophic cardiomyopathy, myocarditis, and valvular disease, are also outlined.

52 palliative care for ischemic heart disease, valvular disease, arrhythmias, peripheral artery disease

53 ovascular diseases using atherosclerosis and valvular disease as exemplars.

54 ore likely than men to have hypertension and valvular disease as the underlying etiology.

55 cterization of the mechanism and severity of valvular disease as well as determining the hemodynamic

56 edicine, such as heart failure, arrhythmias, valvular disease, atherosclerosis, and thrombosis.

57 dge on mechanical intravascular hemolysis in valvular disease, before and after correction, focusing

58 particles carry oxidized lipids that promote valvular disease, but low-density lipoprotein-lowering t

59 lacement was 22 percent in the patients with valvular disease, but only 8 percent in those without it

60 radically shift the treatment landscape for valvular disease by functioning as life-long valve repla

61 phy, dilation or dysfunction, or significant valvular disease), C1 (clinical HF without prior hospita

62 ased age, male sex, acute coronary syndrome, valvular disease, carotid disease, hyperlipidemia, hyper

63 Aortic insufficiency is a valvular disease characterized by left ventricular volum

64 We excluded patients with valvular disease, chronic dialysis, venous thromboemboli

65 ding ischemic heart disease, cardiomyopathy, valvular disease, congenital disease, pericardial diseas

66 Cardiac valvular diseases contribute to >42,000 deaths yearly in

67 han 65 years on April 1, 2002, without prior valvular disease, coronary artery disease, heart failure

68 in diagnosis and treatment of heart failure, valvular disease, coronary disease, and congenital disea

69 For patients without significant valvular disease, decisions around anticoagulation thera

70 ol use, significant coronary artery disease, valvular disease, diabetes mellitus, or pretransplant hy

71 sk factors for AF (body mass index, smoking, valvular disease, diabetes, electrocardiographic left ve

72 lant recipients (ie, pulmonary hypertension, valvular diseases, diastolic dysfunction) and the use of

73 Significant valvular disease did not correlate with the dose or dura

74 disease (eg, unsuspected cardiomyopathy) or valvular disease (eg, mitral valve prolapse) that can pr

75 rtic stenosis (AS) is one of the most common valvular diseases encountered in clinical practice.

76 for the perioperative evaluation of cardiac valvular disease, especially during surgical procedures

77 tery disease, heart failure, and significant valvular disease from the fifth visit of the ARIC study

78 5-hydroxytryptamine (5-HT)]-mediated cardiac valvular disease has been commonly observed in patients

79 ar function, ischemia, pericardial effusion, valvular disease, heart donor status and arrhythmia.

80 re residence, prior anticoagulation therapy, valvular disease, heart failure, hypertension, diabetes,

81 es, including advanced calcific arterial and valvular disease; however, the mechanisms of accelerated

82 ological (such as exercise) or pathological (valvular disease, hypertension, or obesity) increase in

83 morbid conditions (congestive heart failure, valvular disease, hypertension, paralysis, neurologic di

84 c heart disease, cardiomyopathy, significant valvular disease, hyperthyroidism, or hypertension that

85 primary indication for surgery was isolated valvular disease in 41 patients: aortic stenosis (AS; n=

86 ic heart disease is the most common cause of valvular disease in developing countries.

87 tomatic heart disease in general, and aortic valvular disease in particular, following mediastinal ir

88 der the role of molecular imaging in cardiac valvular diseases, including aortic stenosis and valvula

89 ricuspid regurgitation (TR) is a right-sided valvular disease independently associated with morbidity

90 surgical management of patients with aortic valvular disease is described.

91 d pressure <140/90; and absence of diabetes, valvular disease, LV wall motion abnormality, or antihyp

92 f valvulogenesis and in the context of adult valvular disease may recapitulate their embryonic roles.

93 patients with angina pectoris without known valvular disease (n = 95).

94 Neither the presence of valvular disease nor changes in the echocardiographic fi

95 described in the initial report, significant valvular disease on initial postexposure echocardiograph

96 seases of the myocardium, and the effects of valvular disease on myocardial function, and to advance

97 Patients with significant valvular disease or documented contraindication to aspir

98 lder (OR, 1.3 [CI, 1.0 to 1.7]), significant valvular disease (OR, 2.1 [CI, 1.2 to 3.6]), history of

99 n, or surgical or percutaneous treatment for valvular disease, or documented coronary artery disease,

100 gery, hypertrophic cardiomyopathy, rheumatic valvular disease, or greater than mild mitral stenosis).

101 r than 30 years, history of heart failure or valvular disease, pacemaker implantation, and uninterpre

102 logy ranging from congenital to vascular and valvular disease, particularly in structural heart inter

103 der age, diabetes mellitus, and a history of valvular disease predicted both types of HF (P</=0.0025

104 y surveillance and overutilization of TTE in valvular disease provides a model to study variation in

105 tients without a history of heart failure or valvular disease referred for exercise echocardiography

106 Aortic stenosis is the most common valvular disease requiring valve replacement.

107 disease (RR, 6.1), heart failure (RR, 19.4), valvular disease (RR, 13.6), and arrhythmia (RR, 6.0; al

108 r cysts, intracranial aneurysms, and cardiac valvular disease, show that ADPKD is a systemic disorder

109 proportions of deaths from heart failure and valvular disease specifically increased with declining e

110 Vitamin D plays no etiologic role in cardiac valvular disease, such as that observed in Williams synd

111 aortic arch anomalies, left-to-right shunts, valvular disease, tetralogy of Fallot, and truncus arter

112 AS continues to be the most frequent valvular disease that requires intervention, and aortic

113 provide an opportunity to resolve congenital valvular disease, the development of partial heart trans

114 sers of fenfluramine and dexfenfluramine had valvular disease, these drugs were withdrawn from the ma

115 l infarction, cardiomyopathies, arrhythmias, valvular disease, thromboembolic disease, aortic disease

116 rformed a study to determine the relation of valvular disease to other clinical features of lupus, wh

117 mal or persistent AF and without significant valvular disease, uncontrolled hypertension, coronary ar

118 re AS (valve area </= 1 cm(2)) without other valvular disease underwent cardiac catheterization.

119 death resulting from aortic, mitral, and all valvular diseases using a population-based genealogy lin

120 ry artery disease (CAD), heart failure (HF), valvular disease (VD), and arrhythmia.

121 osis, coronary heart disease, heart failure, valvular disease, venous disease, and peripheral artery

122 eart disease, cardiomyopathy, heart failure, valvular disease, venous thromboembolism, and peripheral

123 diography and transthoracic echocardiography.Valvular disease was common and increased with time foll

124 hree with cured IE, and 11 with noninfective valvular disease, were studied.

125 om and adult participants with aortic and/or valvular disease who were enrolled between May and Augus

126 there is only 1 which can resolve congenital valvular disease with 1 operation.

127 duals without prior myocardial infarction or valvular disease, with an adjusted HR of 6.5 (CI 3.1 to

128 s the surprising effect of producing cardiac valvular disease without bone involvement.